Is Sulfanor 33% registered in Zambia?

Sulfanor 33% is recorded with registration status “Registered/Compliant” in Zambia, registration number ZAMRA-VM-26-441, based on ZAMRA data.

Who manufactures Sulfanor 33%?

Sulfanor 33% is manufactured by Shandong Unovet Pharmaceutical Co., Ltd.

Registered Zambia · ZAMRA

Sulfanor 33%

Q: What is the active ingredient in Sulfanor 33%?

Sulfanor 33% contains Sulfamidine Sodium 33 mg/ml, dosage form Sterile suspension for Injection.

Sulfamidine Sodium 33 mg/ml

ZAMRA-VM-26-441 Sterile suspension for Injection

Ask about this medicine

Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.

Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.

Sourcing - Kenya only

Registration & product details

Registration no.

ZAMRA-VM-26-441

Registration date

2026-10-15

Expiry date

2031-10-14

Status

Registered/Compliant

Active ingredient

Sulfamidine Sodium 33 mg/ml

Dosage form

Sterile suspension for Injection

Strength

Pack size

Therapeutic class

Manufacturer / MAH

Shandong Unovet Pharmaceutical Co., Ltd

Applicant / LTR

JUBAILI AGROTEC LIMITED

Country of origin

China

Source: Zambia Medicines Regulatory Authority · fetched 2026-10-19 03:40:05

Disclaimer: This information is sourced from Zambia Medicines Regulatory Authority (Zambia). Always consult a qualified healthcare professional before using any medication.

Molecular reference: sulfamidine

PubChem CID 5327

Molecular formula: C12H14N4O2S

Mechanism of action

Sulfonamides inhibit the enzymatic conversion of pteridine and p-aminobenzoic acid (PABA) to dihydropteroic acid by competing with PABA for binding to dihydrofolate synthetase, an intermediate of tetrahydrofolic acid (THF) synthesis. THF is required for the synthesis of purines and dTMP and inhibition of its synthesis inhibits bacterial growth. Pyrimethamine and trimethoprim inhibit dihydrofolate reductase, another step in THF synthesis, and therefore act synergistically with the sulfonamides.

Pharmacodynamics

Sulfamethazine is a sulfonamide drug that inhibits bacterial synthesis of dihydrofolic acid by competing with para-aminobenzoic acid (PABA) for binding to dihydropteroate synthetase (dihydrofolate synthetase). Sulfamethazine is bacteriostatic in nature. Inhibition of dihydrofolic acid synthesis decreases the synthesis of bacterial nucleotides and DNA.

Source: PubChem (NCBI) · pathways from PathBank, Reactome, WikiPathways & PharmGKB.

This drug in other countries

The same active ingredient registered across other registries we cover - including different brands.